Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag

Anavex Life Sciences

AVXL Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown
AVXL Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
AVXL Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
AVXL Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes in AVXL holdings by institutional investors

Quarterly net insider trading by AVXL's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

  • $40,000 Apr 17, 2026 Issue: Health Issues
  • $60,000 Jan 18, 2026 Issue: Health Issues
  • $60,000 Oct 19, 2025 Issue: Health Issues
  • $60,000 Jul 18, 2025 Issue: Health Issues
  • $60,000 Apr 18, 2025 Issue: Health Issues

Former government officials who have lobbied for AVXL

4 former government officials from 3 congressional offices at 1 lobbying firm have lobbied for AVXL, most recently Jan 18, 2026.

  • Ron Kind
    Cynthia Brown House New Chief of Staff, Rep. Ron Kind (2003-2009) Formerly with Ron Kind · FORBES-TATE · Jan 18, 2026
  • Richard C. Shelby
    Wesley Welch Senate New Legislative Director, Sen. Richard Shelby (2005-2007); Legislative Assistant, Sen. Richard Shelby (2002-2005) Formerly with Richard C. Shelby · FORBES-TATE · Mar 11, 2025
  • Arthur Sidney House New LD & Chief Counsel, Rep. Jackson Lee (2008-2009); Chief of staff and chief counsel, Rep. Johnson (2009-2020) Formerly Jackson Lee · FORBES-TATE · Mar 11, 2025
  • Mike Crapo
    Barrett Thornhill Senate New Legislative Assistant, Sen. Mike Crapo (2003-2006) Formerly with Mike Crapo · FORBES-TATE · Mar 11, 2025

AVXL Estimated quarterly lobbying spending

AVXL Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
AVXL Income Statement
AVXL Balance Sheet
AVXL Cash Flow
U.S. Patents

New AVXL patent grants

  • Patent Title: Neurodevelopmental disorder therapy Sep. 15, 2026
  • Patent Title: Anavex2-73 for the treatment of genetic neurodevelopmental disorders Jun. 02, 2026
  • Patent Title: A19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy Apr. 07, 2026
  • Patent Title: Anavex2-73 for the treatment of genetic neurodevelopmental disorders Feb. 24, 2026
  • Patent Title: Optimized sigma-1 agonist method of responder selection and treatment Aug. 12, 2025
  • Patent Title: A2-73 as a therapeutic for insomnia, anxiety and agitation Apr. 29, 2025
  • Patent Title: Sigma-1 receptor agonist systolic blood pressure therapy Apr. 22, 2025
  • Patent Title: Enantiomers of a2-73, analogues, and sigma agonist activity Jan. 28, 2025
  • Patent Title: A2-73 crystalline polymorph compositions of matter and methods of use thereof Dec. 31, 2024
  • Patent Title: Treatment of cardiac dysfunction Nov. 12, 2024
  • Patent Title: Analgesic therapeutic and method, 1-(3-4(((1r,3s,5s)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof Feb. 13, 2024
  • Patent Title: Neurodevelopmental disorder therapy Dec. 12, 2023
  • Patent Title: A2-73 as a therapeutic for insomnia, anxiety, and agitation Nov. 14, 2023
  • Patent Title: A19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy Jul. 04, 2023
  • Patent Title: Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions May. 30, 2023
  • Patent Title: Sigma-1 receptor agonist systolic blood pressure therapy Apr. 11, 2023
  • Patent Title: A2-73 crystalline polymorph compositions of matter and methods of use thereof Nov. 15, 2022
  • Patent Title: Neurodevelopmental disorder therapy Sep. 20, 2022
  • Patent Title: A2-73 as a therapeutic for insomnia, anxiety, and agitation May. 24, 2022
  • Patent Title: Anavex2-73 for the treatment of alzheimer's disease Aug. 31, 2021
  • Patent Title: Treatment of cardiac dysfunction Jul. 27, 2021
  • Patent Title: Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions Apr. 06, 2021
  • Patent Title: Analgesic therapeutic and method, 1-(3-4(((1 r,3s,5s)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof Mar. 02, 2021
  • Patent Title: Neurodevelopmental disorder therapy Jan. 12, 2021
  • Patent Title: A19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy Oct. 27, 2020
  • Patent Title: Neurodevelopmental disorder therapy Dec. 17, 2019
  • Patent Title: A19-144, a2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapy Oct. 15, 2019
  • Patent Title: Crystalline form of anavex2-73 for the treatment of alzheimer's disease Oct. 01, 2019
  • Patent Title: Crystal forms of tetrahydro-n,n-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, processes of making such forms, and their pharmaceutical compositions Sep. 17, 2019
  • Patent Title: Analgesic therapeutic and method, 1-(3-4(((1r,3s,5s)-adamantan-1-yl)(phenyl)methyl)propyl)-4-methylpiperazine and salts thereof Feb. 05, 2019
  • Patent Title: Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotection Sep. 05, 2017
  • Patent Title: Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activity Nov. 10, 2015
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to AVXL from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
AVXL News

Recent insights relating to AVXL

CNBC Recommendations

Recent picks made for AVXL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AVXL

AVXL Analyst Ratings

AVXL Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
AVXL Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $AVXL stock a Buy, Sell, or Hold?

  • What is the price target for $AVXL stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

AVXL Top Shareholders
Shareholder
Shares Held
AVXL Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $AVXL stock?

  • Who owns the most shares of $AVXL stock?

  • What funds own $AVXL stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

AVXL Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view AVXL Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About AVXL

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

  • Address New York, NY
  • Market Cap 220.6 million
  • Employees 34
  • Industrial Classification Biological Products, (No Diagnostic Substances)

Anavex Life Sciences (AVXL) Historical Stock Prices

Anavex Life Sciences (AVXL) closed at $2.38 on September 25, 2026. Over the past year its adjusted close ranged from $2.34 to $9.96. Daily prices go back to January 2, 2014, 3,186 trading days in all.

  • 1 month-26.54%
  • 3 months-9.16%
  • Year to date-33.15%
  • 1 year-72.00%
  • 3 years-65.00%
  • 5 years-87.30%
  • Max+750.00%
See every congressional and insider trade on the AVXL price chart

Quiver Premium charts AVXL's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 25, 2026 2.35 2.43 2.32 2.38 2.38 744,392
Sep 24, 2026 2.33 2.37 2.27 2.34 2.34 937,052
Sep 23, 2026 2.47 2.49 2.31 2.35 2.35 779,167
Sep 22, 2026 2.41 2.48 2.39 2.47 2.47 639,992
Sep 21, 2026 2.42 2.42 2.35 2.40 2.40 574,478
Sep 18, 2026 2.42 2.45 2.38 2.42 2.42 920,588
Sep 17, 2026 2.41 2.48 2.40 2.41 2.41 364,751
Sep 16, 2026 2.44 2.47 2.31 2.36 2.36 906,104
Sep 15, 2026 2.59 2.59 2.43 2.44 2.44 946,237
Sep 14, 2026 2.61 2.64 2.55 2.60 2.60 658,133
Sep 11, 2026 2.71 2.74 2.61 2.62 2.62 624,490
Sep 10, 2026 2.71 2.73 2.62 2.66 2.66 433,767
Sep 9, 2026 2.84 2.90 2.74 2.75 2.75 438,581
Sep 8, 2026 2.81 2.88 2.77 2.85 2.85 559,135
Sep 4, 2026 2.82 2.90 2.81 2.86 2.86 307,150
Sep 3, 2026 2.90 2.94 2.82 2.85 2.85 421,922
Sep 2, 2026 2.88 2.98 2.81 2.89 2.89 587,453
Sep 1, 2026 2.79 2.90 2.75 2.87 2.87 826,676
Aug 31, 2026 2.95 2.97 2.78 2.80 2.80 1,034,003
Aug 28, 2026 3.12 3.13 2.96 2.99 2.99 893,447
Aug 27, 2026 3.25 3.26 3.12 3.13 3.13 652,701
Aug 26, 2026 3.50 3.54 3.22 3.24 3.24 1,180,598
Aug 25, 2026 3.37 3.68 3.37 3.56 3.56 2,475,503
Aug 24, 2026 3.22 3.23 3.09 3.11 3.11 457,402
Aug 21, 2026 3.17 3.29 3.16 3.24 3.24 480,788
Aug 20, 2026 3.34 3.36 3.09 3.13 3.13 557,176
Aug 19, 2026 3.20 3.41 3.20 3.39 3.39 655,292
Aug 18, 2026 3.16 3.22 3.10 3.20 3.20 400,665
Aug 17, 2026 3.19 3.23 3.15 3.21 3.21 464,791
Aug 14, 2026 3.25 3.27 3.14 3.22 3.22 698,066
Aug 13, 2026 3.40 3.40 3.22 3.27 3.27 829,934
Aug 12, 2026 3.50 3.57 3.40 3.41 3.41 667,078
Aug 11, 2026 3.37 3.54 3.36 3.51 3.51 662,617
Aug 10, 2026 3.33 3.44 3.28 3.39 3.39 668,800
Aug 7, 2026 3.33 3.40 3.32 3.34 3.34 1,045,897
Aug 6, 2026 3.17 3.32 3.16 3.28 3.28 856,158
Aug 5, 2026 3.18 3.26 3.12 3.20 3.20 1,166,258
Aug 4, 2026 2.94 3.30 2.94 3.15 3.15 1,977,762
Aug 3, 2026 2.80 2.97 2.74 2.95 2.95 1,444,021
Jul 31, 2026 2.67 2.77 2.66 2.75 2.75 1,198,642
Jul 30, 2026 2.51 2.71 2.51 2.70 2.70 1,249,725
Jul 29, 2026 2.56 2.60 2.48 2.49 2.49 1,100,062
Jul 28, 2026 2.48 2.60 2.47 2.57 2.57 775,993
Jul 27, 2026 2.41 2.54 2.38 2.50 2.50 716,573
Jul 24, 2026 2.48 2.50 2.39 2.40 2.40 1,012,626
Jul 23, 2026 2.48 2.56 2.46 2.48 2.48 1,179,850
Jul 22, 2026 2.54 2.60 2.51 2.55 2.55 656,175
Jul 21, 2026 2.39 2.59 2.39 2.56 2.56 829,804
Jul 20, 2026 2.41 2.45 2.37 2.42 2.42 850,670
Jul 17, 2026 2.28 2.43 2.25 2.39 2.39 1,921,050
Jul 16, 2026 2.47 2.47 2.29 2.34 2.34 763,693
Jul 15, 2026 2.44 2.50 2.40 2.50 2.50 732,024
Jul 14, 2026 2.33 2.48 2.30 2.43 2.43 885,549
Jul 13, 2026 2.46 2.51 2.30 2.35 2.35 1,319,075
Jul 10, 2026 2.70 2.71 2.42 2.50 2.50 749,693
Jul 9, 2026 2.71 2.75 2.63 2.70 2.70 895,752
Jul 8, 2026 2.67 2.79 2.65 2.70 2.70 776,516
Jul 7, 2026 2.69 2.73 2.60 2.71 2.71 851,504
Jul 6, 2026 2.77 2.77 2.66 2.66 2.66 636,985
Jul 2, 2026 2.60 2.79 2.57 2.76 2.76 1,175,012
Jul 1, 2026 2.59 2.63 2.56 2.58 2.58 1,128,377
Jun 30, 2026 2.56 2.66 2.56 2.59 2.59 893,018
Jun 29, 2026 2.62 2.64 2.50 2.60 2.60 796,782
Jun 26, 2026 2.46 2.63 2.46 2.62 2.62 4,198,743
Jun 25, 2026 2.58 2.58 2.46 2.46 2.46 940,984
Jun 24, 2026 2.57 2.67 2.55 2.56 2.56 758,929
Jun 23, 2026 2.50 2.67 2.49 2.58 2.58 780,949
Jun 22, 2026 2.73 2.80 2.53 2.54 2.54 1,154,862
Jun 18, 2026 2.73 2.78 2.58 2.73 2.73 8,914,887
Jun 17, 2026 2.60 2.77 2.56 2.67 2.67 1,478,032
Jun 16, 2026 2.49 2.54 2.44 2.52 2.52 951,276
Jun 15, 2026 2.55 2.58 2.47 2.50 2.50 934,374
Jun 12, 2026 2.50 2.58 2.45 2.50 2.50 1,222,155
Jun 11, 2026 2.44 2.54 2.41 2.50 2.50 974,780
Jun 10, 2026 2.53 2.58 2.46 2.46 2.46 921,873
Jun 9, 2026 2.65 2.73 2.48 2.54 2.54 868,983
Jun 8, 2026 2.61 2.64 2.54 2.62 2.62 895,049
Jun 5, 2026 2.82 2.82 2.56 2.57 2.57 942,449
Jun 4, 2026 2.68 2.91 2.65 2.82 2.82 937,735
Jun 3, 2026 2.73 2.75 2.61 2.65 2.65 1,054,060
Jun 2, 2026 2.98 2.98 2.68 2.79 2.79 2,421,421
Jun 1, 2026 2.99 3.07 2.91 2.98 2.98 1,592,963
May 29, 2026 2.95 3.04 2.81 3.03 3.03 1,314,606
May 28, 2026 2.78 2.98 2.78 2.94 2.94 1,421,852
May 27, 2026 2.70 2.84 2.68 2.76 2.76 1,157,512
May 26, 2026 2.69 2.80 2.65 2.71 2.71 924,437
May 22, 2026 2.70 2.74 2.63 2.69 2.69 1,119,999
May 21, 2026 2.72 2.79 2.68 2.71 2.71 954,708
May 20, 2026 2.68 2.76 2.67 2.75 2.75 880,525
May 19, 2026 2.86 2.88 2.67 2.67 2.67 1,563,240
May 18, 2026 2.92 2.98 2.83 2.88 2.88 937,110
May 15, 2026 3.04 3.06 2.88 2.91 2.91 1,216,467
May 14, 2026 3.07 3.14 2.94 3.08 3.08 1,250,747
May 13, 2026 3.02 3.10 3.01 3.08 3.08 1,244,413
May 12, 2026 3.24 3.30 3.02 3.06 3.06 1,236,108
May 11, 2026 3.19 3.36 3.16 3.24 3.24 1,063,270
May 8, 2026 3.12 3.25 3.12 3.22 3.22 735,529
May 7, 2026 3.34 3.39 3.12 3.12 3.12 1,318,381
May 6, 2026 3.25 3.35 3.06 3.34 3.34 1,088,180
May 5, 2026 3.45 3.49 3.33 3.36 3.36 480,400
May 4, 2026 3.35 3.50 3.35 3.41 3.41 726,205
May 1, 2026 3.32 3.35 3.27 3.32 3.32 505,436
Apr 30, 2026 3.28 3.42 3.26 3.34 3.34 651,097
Apr 29, 2026 3.30 3.34 3.23 3.26 3.26 618,675
Apr 28, 2026 3.23 3.38 3.23 3.37 3.37 616,667
Apr 27, 2026 3.34 3.44 3.25 3.29 3.29 739,779
Apr 24, 2026 3.34 3.41 3.23 3.34 3.34 617,587
Apr 23, 2026 3.53 3.58 3.26 3.31 3.31 986,931
Apr 22, 2026 3.58 3.69 3.52 3.61 3.61 752,380
Apr 21, 2026 3.67 3.69 3.48 3.50 3.50 769,818
Apr 20, 2026 3.57 3.75 3.54 3.65 3.65 1,138,258
Apr 17, 2026 3.46 3.68 3.45 3.64 3.64 1,541,672
Apr 16, 2026 3.25 3.42 3.24 3.40 3.40 817,236
Apr 15, 2026 3.15 3.25 3.11 3.24 3.24 993,762
Apr 14, 2026 3.15 3.31 3.04 3.12 3.12 1,789,067
Apr 13, 2026 2.95 3.13 2.93 3.11 3.11 907,706
Apr 10, 2026 3.06 3.08 2.90 2.95 2.95 1,039,887
Apr 9, 2026 3.00 3.12 2.98 3.05 3.05 795,286
Apr 8, 2026 3.18 3.23 3.02 3.04 3.04 1,022,307
Apr 7, 2026 2.92 3.10 2.87 3.08 3.08 1,073,280
Apr 6, 2026 3.02 3.09 2.95 2.96 2.96 1,004,774
Apr 2, 2026 3.04 3.06 2.95 2.99 2.99 1,166,347
Apr 1, 2026 3.08 3.19 3.06 3.10 3.10 1,345,723
Mar 31, 2026 2.85 3.09 2.85 3.07 3.07 1,875,508
Mar 30, 2026 2.75 2.85 2.69 2.82 2.82 1,570,511
Mar 27, 2026 2.83 2.89 2.75 2.82 2.82 2,432,197
Mar 26, 2026 2.71 3.02 2.65 2.88 2.88 3,912,047
Mar 25, 2026 3.01 3.12 2.61 2.74 2.74 14,061,074
Mar 24, 2026 4.47 4.55 4.16 4.19 4.19 1,040,748
Mar 23, 2026 4.10 4.61 4.10 4.44 4.44 2,108,099
Mar 20, 2026 4.20 4.28 4.04 4.06 4.06 2,767,786
Mar 19, 2026 4.20 4.32 4.06 4.20 4.20 1,576,962
Mar 18, 2026 4.51 4.51 4.25 4.26 4.26 907,901
Mar 17, 2026 4.75 4.82 4.52 4.55 4.55 1,047,819
Mar 16, 2026 4.75 4.83 4.67 4.71 4.71 493,560
Mar 13, 2026 4.71 4.87 4.63 4.65 4.65 989,415
Mar 12, 2026 4.58 4.68 4.39 4.65 4.65 963,475
Mar 11, 2026 4.62 4.69 4.52 4.65 4.65 594,730
Mar 10, 2026 4.78 4.83 4.55 4.64 4.64 701,337
Mar 9, 2026 4.68 4.90 4.62 4.79 4.79 900,614
Mar 6, 2026 4.66 4.74 4.42 4.65 4.65 1,206,882
Mar 5, 2026 5.00 5.02 4.70 4.76 4.76 1,085,731
Mar 4, 2026 4.66 5.18 4.62 5.00 5.00 1,499,558
Mar 3, 2026 4.45 4.74 4.45 4.69 4.69 1,217,999
Mar 2, 2026 4.31 4.66 4.30 4.53 4.53 922,817
Feb 27, 2026 4.40 4.46 4.28 4.43 4.43 2,385,124
Feb 26, 2026 4.43 4.49 4.24 4.46 4.46 858,850
Feb 25, 2026 4.40 4.70 4.36 4.40 4.40 1,189,417
Feb 24, 2026 4.17 4.42 4.15 4.36 4.36 1,013,286
Feb 23, 2026 4.09 4.24 4.07 4.16 4.16 573,845
Feb 20, 2026 4.15 4.18 4.07 4.12 4.12 800,557
Feb 19, 2026 4.13 4.14 4.00 4.12 4.12 736,066
Feb 18, 2026 4.03 4.16 4.00 4.04 4.04 933,154
Feb 17, 2026 3.97 4.09 3.89 4.04 4.04 886,567
Feb 13, 2026 3.98 4.18 3.91 3.93 3.93 1,080,530
Feb 12, 2026 3.90 4.00 3.77 3.92 3.92 1,338,195
Feb 11, 2026 3.97 4.04 3.75 3.88 3.88 1,407,224
Feb 10, 2026 4.34 4.35 3.95 3.96 3.96 1,669,461
Feb 9, 2026 4.20 4.54 4.07 4.35 4.35 1,800,254
Feb 6, 2026 3.86 4.26 3.82 4.10 4.10 1,681,796
Feb 5, 2026 4.14 4.19 3.81 3.81 3.81 1,440,435
Feb 4, 2026 4.44 4.44 4.10 4.13 4.13 2,621,191
Feb 3, 2026 4.50 4.65 4.33 4.39 4.39 1,268,783
Feb 2, 2026 4.62 4.70 4.49 4.52 4.52 1,391,937
Jan 30, 2026 4.83 5.05 4.68 4.70 4.70 1,834,417
Jan 29, 2026 4.86 4.99 4.78 4.91 4.91 744,867
Jan 28, 2026 5.06 5.06 4.85 4.87 4.87 908,339
Jan 27, 2026 4.96 5.07 4.86 5.05 5.05 830,593
Jan 26, 2026 5.20 5.20 4.95 5.02 5.02 873,866
Jan 23, 2026 5.25 5.32 5.05 5.26 5.26 1,229,748
Jan 22, 2026 5.30 5.36 5.18 5.30 5.30 1,134,291
Jan 21, 2026 5.03 5.35 4.95 5.30 5.30 1,425,553
Jan 20, 2026 4.87 5.21 4.78 5.03 5.03 1,708,855
Jan 16, 2026 4.87 5.19 4.73 5.01 5.01 1,735,973
Jan 15, 2026 4.88 4.96 4.67 4.85 4.85 1,138,914
Jan 14, 2026 4.68 4.91 4.67 4.82 4.82 2,134,770
Jan 13, 2026 4.37 4.70 4.21 4.64 4.64 1,874,588
Jan 12, 2026 4.30 4.34 4.11 4.29 4.29 987,578
Jan 9, 2026 4.37 4.43 4.20 4.28 4.28 1,484,962
Jan 8, 2026 4.09 4.31 3.97 4.27 4.27 1,270,709
Jan 7, 2026 3.99 4.20 3.97 4.10 4.10 1,600,328
Jan 6, 2026 4.12 4.37 3.98 4.01 4.01 2,708,650
Jan 5, 2026 3.66 3.98 3.65 3.95 3.95 1,559,650
Jan 2, 2026 3.63 3.71 3.50 3.68 3.68 1,554,116
Dec 31, 2025 3.77 3.78 3.52 3.56 3.56 1,513,848
Dec 30, 2025 3.65 3.82 3.62 3.80 3.80 4,948,300
Dec 29, 2025 3.59 3.72 3.57 3.65 3.65 1,714,512
Dec 26, 2025 3.69 3.74 3.57 3.64 3.64 1,614,383
Dec 24, 2025 3.71 3.80 3.65 3.72 3.72 953,792
Dec 23, 2025 3.76 3.81 3.66 3.73 3.73 2,094,334
Dec 22, 2025 3.62 3.82 3.56 3.75 3.75 2,555,316
Dec 19, 2025 3.90 4.01 3.60 3.67 3.67 5,279,851
Dec 18, 2025 3.98 4.08 3.79 3.89 3.89 1,793,228
Dec 17, 2025 3.99 4.09 3.81 3.92 3.92 2,887,537
Dec 16, 2025 4.04 4.22 3.94 4.02 4.02 1,935,209
Dec 15, 2025 3.93 4.22 3.87 4.14 4.14 2,329,347
Dec 12, 2025 3.67 4.16 3.66 4.02 4.02 4,861,956
Dec 11, 2025 4.00 4.17 3.98 4.11 4.11 1,566,328
Dec 10, 2025 4.36 4.40 3.96 4.08 4.08 1,609,979
Dec 9, 2025 4.30 4.58 4.21 4.41 4.41 1,150,196
Dec 8, 2025 4.48 4.88 4.33 4.34 4.34 1,529,283
Dec 5, 2025 4.43 4.52 4.32 4.40 4.40 1,077,696
Dec 4, 2025 4.49 4.58 4.29 4.45 4.45 1,868,245
Dec 3, 2025 3.80 4.84 3.80 4.57 4.57 7,460,212
Dec 2, 2025 3.80 3.94 3.62 3.67 3.67 1,834,773
Dec 1, 2025 3.83 4.05 3.67 3.82 3.82 3,082,887
Nov 28, 2025 3.93 3.96 3.73 3.83 3.83 1,682,915
Nov 26, 2025 3.55 3.92 3.46 3.86 3.86 3,767,652
Nov 25, 2025 3.29 3.69 3.18 3.46 3.46 4,525,581
Nov 24, 2025 3.23 3.29 3.00 3.08 3.08 3,999,703
Nov 21, 2025 3.17 3.37 3.13 3.26 3.26 2,795,354
Nov 20, 2025 3.58 3.65 3.05 3.17 3.17 5,827,619
Nov 19, 2025 3.47 3.74 3.40 3.60 3.60 2,212,395
Nov 18, 2025 3.54 3.64 3.44 3.50 3.50 2,697,005
Nov 17, 2025 3.50 4.04 3.28 3.58 3.58 6,351,892
Nov 14, 2025 2.96 4.14 2.86 3.65 3.65 22,984,265
Nov 13, 2025 6.90 7.25 5.10 5.69 5.69 8,747,216
Nov 12, 2025 6.79 6.99 6.55 6.90 6.90 1,704,360
Nov 11, 2025 6.59 6.95 6.49 6.85 6.85 2,288,853
Nov 10, 2025 7.56 7.60 6.35 6.49 6.49 4,638,673
Nov 7, 2025 7.41 7.54 7.11 7.29 7.29 1,599,329
Nov 6, 2025 7.30 7.59 7.22 7.40 7.40 1,142,370
Nov 5, 2025 7.40 7.51 7.27 7.31 7.31 1,545,875
Nov 4, 2025 7.65 7.79 7.44 7.47 7.47 1,031,641
Nov 3, 2025 7.90 7.94 7.45 7.74 7.74 1,657,000
Oct 31, 2025 8.05 8.14 7.85 7.97 7.97 1,351,238
Oct 30, 2025 8.00 8.35 7.98 8.03 8.03 805,872
Oct 29, 2025 8.10 8.32 7.88 8.02 8.02 1,544,951
Oct 28, 2025 8.43 8.45 8.06 8.10 8.10 1,239,283
Oct 27, 2025 8.70 8.79 8.35 8.49 8.49 1,059,356
Oct 24, 2025 8.81 8.97 8.58 8.62 8.62 804,625
Oct 23, 2025 9.29 9.40 8.41 8.74 8.74 1,494,875
Oct 22, 2025 9.35 9.50 9.18 9.35 9.35 568,623
Oct 21, 2025 9.35 9.48 9.26 9.35 9.35 516,869
Oct 20, 2025 9.14 9.50 9.03 9.36 9.36 1,061,808
Oct 17, 2025 8.90 9.25 8.89 8.98 8.98 749,318
Oct 16, 2025 9.00 9.28 8.89 9.01 9.01 987,185
Oct 15, 2025 8.80 9.08 8.66 9.03 9.03 1,055,267
Oct 14, 2025 8.58 9.04 8.06 8.79 8.79 1,112,044
Oct 13, 2025 9.29 9.29 8.34 8.62 8.62 2,318,476
Oct 10, 2025 9.44 9.53 9.00 9.27 9.27 3,566,696
Oct 9, 2025 9.83 9.95 9.51 9.52 9.52 1,385,565
Oct 8, 2025 9.81 10.10 9.73 9.85 9.85 1,177,058
Oct 7, 2025 9.65 10.38 9.60 9.78 9.78 1,800,265
Oct 6, 2025 10.00 10.07 9.54 9.61 9.61 1,056,507
Oct 3, 2025 9.13 10.04 9.02 9.96 9.96 1,868,234
Oct 2, 2025 9.19 9.65 8.80 9.13 9.13 2,585,170
Oct 1, 2025 8.92 9.32 8.89 9.01 9.01 1,069,359
Sep 30, 2025 8.70 9.01 8.68 8.90 8.90 1,106,524
Sep 29, 2025 8.68 8.82 8.57 8.65 8.65 752,254
Sep 26, 2025 8.44 8.74 8.43 8.66 8.66 806,392
Sep 25, 2025 8.32 8.71 8.32 8.50 8.50 690,548

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Anavex Life Sciences Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at AVXL, per a recent SEC DEF 14A filing. We estimate that the median employee at ANAVEX LIFE SCIENCES CORP. is paid $324,729.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation